Leads Biolabs’ Opamtistomig and LBL-034 Featured in Six ESMO Abstracts
Six abstracts feature the company's drug candidates at the 2026 ESMO Congress; three were selected for oral presentation, including one late-breaking abstract. The release highlights durable responses and long-term survival signals across immunologically cold tumors, and deep, sustained responses in multiple myeloma.